Danaher Corporation (NYSE:DHR) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC lowered its stake in Danaher Corporation (NYSE:DHR - Free Report) by 32.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,918 shares of the conglomerate's stock after selling 8,299 shares during the quarter. Kintegral Advisory LLC's holdings in Danaher were worth $3,474,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of DHR. Bank Pictet & Cie Europe AG grew its holdings in Danaher by 22.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after purchasing an additional 35,730 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in Danaher by 1.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 33,706 shares of the conglomerate's stock valued at $7,737,000 after purchasing an additional 595 shares during the last quarter. Bahl & Gaynor Inc. grew its stake in Danaher by 13.2% during the 4th quarter. Bahl & Gaynor Inc. now owns 3,061 shares of the conglomerate's stock valued at $703,000 after purchasing an additional 357 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Danaher by 2.2% during the 4th quarter. Victory Capital Management Inc. now owns 238,148 shares of the conglomerate's stock worth $54,667,000 after purchasing an additional 5,161 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in Danaher by 4.6% during the 4th quarter. Assetmark Inc. now owns 70,304 shares of the conglomerate's stock worth $16,138,000 after purchasing an additional 3,070 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DHR. Argus cut their target price on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. TD Cowen lifted their price target on shares of Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a report on Wednesday, April 23rd. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. The Goldman Sachs Group decreased their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Finally, Wells Fargo & Company dropped their price target on Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 23rd. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $248.61.

Insider Transactions at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

Danaher Stock Performance

Shares of DHR opened at $203.08 on Friday. The firm has a market capitalization of $145.33 billion, a PE ratio of 39.43, a P/E/G ratio of 2.84 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average price of $195.52 and a 200 day moving average price of $207.59. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's dividend payout ratio is currently 24.85%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.